CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 63 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,123,947 | +25.6% | 372,146 | +82.9% | 0.01% | +42.9% |
| Q2 2023 | $6,467,644 | +46.3% | 203,449 | +12.3% | 0.01% | +40.0% |
| Q1 2023 | $4,420,029 | -24.5% | 181,223 | -2.3% | 0.01% | -28.6% |
| Q4 2022 | $5,852,058 | +13.2% | 185,544 | 0.0% | 0.01% | +16.7% |
| Q3 2022 | $5,171,000 | +6.9% | 185,544 | +1.4% | 0.01% | 0.0% |
| Q2 2022 | $4,839,000 | -29.4% | 183,008 | -6.5% | 0.01% | 0.0% |
| Q1 2022 | $6,855,000 | -2.2% | 195,808 | -9.4% | 0.01% | 0.0% |
| Q4 2021 | $7,006,000 | +36.1% | 216,108 | +23.9% | 0.01% | +20.0% |
| Q3 2021 | $5,147,000 | +35.1% | 174,476 | +12.9% | 0.01% | +25.0% |
| Q2 2021 | $3,809,000 | +141.8% | 154,590 | +34.8% | 0.00% | +100.0% |
| Q1 2021 | $1,575,000 | +155.7% | 114,715 | +208.7% | 0.00% | +100.0% |
| Q4 2020 | $616,000 | – | 37,158 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,713,470,000 | 41.39% |
| Perceptive Advisors | 6,511,727 | $184,021,000 | 5.34% |
| Finepoint Capital LP | 536,901 | $15,173,000 | 4.99% |
| Artal Group S.A. | 2,000,000 | $56,520,000 | 2.41% |
| Rock Springs Capital Management LP | 2,499,148 | $70,626,000 | 1.82% |
| Ikarian Capital, LLC | 178,100 | $5,033,000 | 1.00% |
| Hood River Capital Management LLC | 896,572 | $25,337,000 | 0.97% |
| Frazier Life Sciences Management, L.P. | 393,000 | $11,106,000 | 0.86% |
| HighVista Strategies LLC | 23,611 | $667,000 | 0.38% |
| FEDERATED HERMES, INC. | 3,313,333 | $93,635,000 | 0.27% |